Literature DB >> 1699216

Metastatic renal cell cancer--is the outlook really improving?

J Waxman1, H Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1699216      PMCID： PMC2429602          DOI： 10.1136/pgmj.66.776.435

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  35 in total

1.  Antitumor effects of human lymphoblastoid interferon on advanced renal cell carcinoma.

Authors:  T Fujita; H Asano; Y Naide; Y Ono; S Ohshima; K Suzuki; Y Aso; Y Ariyoshi; M Fukushima; K Ota
Journal:  J Urol       Date:  1988-02       Impact factor: 7.450

Review 2.  Therapeutic options in renal cell carcinoma.

Authors:  A C Buzaid; M B Todd
Journal:  Semin Oncol       Date:  1989-02       Impact factor: 4.929

3.  Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer.

Authors:  J P Bergerat; R Herbrecht; P Dufour; D Jacqmin; C Bollack; G Prevot; G Bailly; S de Garis; F Juraschek; F Oberling
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

4.  Myocardial injury after interleukin-2 therapy.

Authors:  S Osanto; F H Cluitmans; C R Franks; H A Bosker; F J Cleton
Journal:  Lancet       Date:  1988-07-02       Impact factor: 79.321

Review 5.  The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.

Authors:  S A Rosenberg
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

6.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

7.  A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity.

Authors:  T J Eberlein; D D Schoof; S E Jung; D Davidson; B Gramolini; K McGrath; A Massaro; R E Wilson
Journal:  Arch Intern Med       Date:  1988-12

8.  Deoxyribonucleic acid content and medroxyprogesterone acetate treatment in metastatic renal cell carcinoma.

Authors:  B Ljungberg; R Tomić; G Roos
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

9.  A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease.

Authors:  D J Gottlieb; M K Brenner; H E Heslop; A C Bianchi; C Bello-Fernandez; A B Mehta; A C Newland; A R Galazka; E M Scott; A V Hoffbrand
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

10.  Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer.

Authors:  H J Bloom
Journal:  Br J Cancer       Date:  1971-06       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.